Mer­ck ex­tends ADC push by lend­ing a hand to C4 with small up­front for pro­tein de­grad­er work

Mer­ck is once again wad­ing in­to the an­ti­body-drug con­ju­gate space af­ter mak­ing a splash with its multi­bil­lion-dol­lar Dai­ichi Sankyo deal at this year’s ES­MO con­fer­ence …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER